The interest of neuro-oncology in the development of IDH inhibitors in different disease settings (for example high-risk patients or enhancing high-grade gliomas) and/or in association with other anti-cancer agents is very high: several phase I trials are underway, aiming to evaluate the efficacy of vorasidenib in combination with tumor specific peptide vaccine (NCT05609994) and in combination with pembrolizumab (NCT05484622). This evidence concerns the gene IDH2 and central nervous system cancer.